stockrow
Saturday 7 November 2026
Export VYGR’s income statement to Excel — free account
Voyager Therapeutics, Inc.
VYGR Healthcare Biotechnology
Voyager Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.4 million, down 49.5% from fiscal 2024.
- Revenue
- −70.0%
- EPS
- +14.9%
- Free cash flow
- +37.1%
Quarter to September 2026, against a year earlier
1.90
0.18
+10.47%
Follow VYGR
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.60 | 6.15 | 6.29 | 5.71 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.43) | (8.20) | (6.87) | (7.62) | |
P/B ratio |
1.23 | 1.37 | 1.32 | 1.18 | |
Price to Tangible BV |
1.23 | 1.37 | 1.32 | 1.18 | |
EV/Sales |
2.35 | 2.77 | 2.42 | 0.85 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.54) | (0.79) | (0.69) | (0.26) | |
EV/FCF |
(0.54) | (0.79) | (0.68) | (0.25) | |
Quick Ratio |
6.61 | 7.16 | 8.20 | 7.47 | |
Current Ratio |
6.81 | 7.51 | 8.42 | 7.64 | |
Net Debt/EBITDA |
4.15 | 4.52 | 4.76 | 6.68 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.11 | 0.13 | 0.13 | 0.13 | |
Operating CF/Net income |
0.80 | 1.06 | 1.20 | 1.10 | |
Capex/Depreciation |
0.00 | 0.00 | (0.02) | (1.21) | |
Research and Development Expense of Revenue |
607.15% | 696.40% | 948.79% | 234.43% | |
Selling, General and Administrative Expense of Revenue |
151.10% | 237.47% | 318.59% | 60.75% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
64.85% | 76.87% | 95.95% | 22.96% | |
Graham Net Nets |
0.44 | 0.39 | 0.44 | 0.64 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(64.93%) | (51.71%) | (51.30%) | (51.91%) | |
Free Cash Flow Yield |
(66.41%) | (57.30%) | (56.58%) | (58.56%) | |
Revenue per Share |
0.06 | 0.05 | 0.04 | 0.26 | |
Operating CF per Share |
(0.32) | (0.43) | (0.56) | (0.52) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.32) | (0.43) | (0.56) | (0.53) | |
Cash per Share |
1.73 | 1.92 | 2.38 | 3.35 | |
Shareholders Equity per Share |
2.19 | 2.55 | 2.92 | 3.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.19 | 2.55 | 2.92 | 3.34 | |
Free Cash Flow |
(19.67) | (25.84) | (33.43) | (30.89) | |
Working Capital |
97.62 | 108.54 | 129.53 | 176.15 | |
Capital Expenditures |
— | 0.00 | (0.01) | (0.63) | |
Net Current Asset Value |
72.49 | 81.85 | 101.33 | 146.49 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.16 | 2.84 | 1.88 | 2.05 | |
Average Payables |
2.03 | 1.71 | 2.68 | 4.50 | |
Average Assets |
232.68 | 259.93 | 286.28 | 322.67 | |
Average Common Equity |
177.47 | 199.16 | 223.19 | 247.92 |
Columns are period end dates · fundamentals updated 5 Nov 2026